Composition comprising glyceryl nonanoate and lipase inhibitor

Abstract

The invention relates to compositions comprising glyceryl nonanoate and a lipase inhibitor and their use.

Description

[0001] Composition comprising glyceryl nonanoate and lipase inhibitor

[0002] Field of the invention

[0003] The invention relates to compositions comprising glyceryl nonanoate and a lipase inhibitor and their use.

[0004] Prior art

[0005] A lot of formulations need to be stabilized for storage at room temperature, especially microbial growth needs to be prevented.

[0006] There are quite some microbial preservatives known in the art, yet most of them are also not well tolerated by higher developed organisms.

[0007] There is a need to provide compositions which are well tolerated by higher organisms and are environmentally friendly.

[0008] The use of antimicrobial agents in cosmetic and pharmaceutical formulations ensures their safe use by effectively killing microorganisms. Nevertheless, even reliable preservation systems are increasingly failing to kill certain microorganisms that have become resistant. These resistant organisms often proliferate in the formulation after the population has been initially decimated (phoenix effect). Therefore, synergistic effects of antimicrobial substances and blends are essential to effectively and specifically kill these "problem germs". A prominent and characteristic example of such a “problem germ” is the gram-negative Pluralibacter gergoviae.

[0009] It is an object of the invention to provide a microbial active composition which overcome the disadvantages of the prior art.

[0010] Description of the invention

[0011] It was found that, surprisingly, compositions comprising glyceryl nonanoate and at least one lipase inhibitor solve the problem known from the prior art.

[0012] The present invention therefore provides compositions comprising at least one glyceryl ester of nonanoic acid and at least one lipase inhibitor.

[0013] Another advantage of the present invention are the excellent antimicrobial properties of the compositions. Another advantage of the present invention are the excellent antimicrobial properties of the composition against problematic resistant germs.

[0014] Another advantage of the present invention are the mild effects on the skin, allowing for an improved selective performance of antimicrobial actives in the formulation on the skin.

[0015] Another advantage of the present invention is its microbiome-friendliness.

[0016] Another advantage of the present invention is its mildness regarding skin-friendliness.

[0017] Another advantage of the formulation is, due to its antimicrobial performance, that other antimicrobials and preservatives can be reduced in the formulation.

[0018] Another advantage of the present invention is that other ingredients in the formulation are protected from decay and therefore, storage stability of the formulation is increased.

[0019] Another advantage of the formulation is its convenience in applying it to formulations.

[0020] Another advantage of the present invention is the improved odor of the pelargonic acid based compositions compared to market standards that are typically based on caprylic acid.

[0021] Another advantage of the compositions of the present invention is that these accelerate the emulsion formation. Improved emulsification properties can lead to shorter production times or energy saving by lower stirring input.

[0022] Another advantage of the present invention is that the compositions resulted in emulsions with improved shine and gloss.

[0023] Another advantage of the compositions of the present invention is the antimicrobial performance against specific germs causing malodor.

[0024] A further advantage of the compositions of the present invention is the boosting of the antimicrobial performance against germs causing Athlete’s foot.

[0025] A further advantage of the compositions of the present invention is that these can mask the undesired odors of other ingredients in the formulation or also in the pure mixtures. It leads to less perfume or flavor usage in the formulations.

[0026] Another advantage is that the compositions of the present invention provide a good thickening performance in cleansing formulations.

[0027] A further advantage of the compositions of the present invention is that these build stable W / O formulation whereas the non-inventive materials like Glyceryl Monocaprylate show instability under the same conditions.

[0028] The present invention therefore provides a composition comprising A) at least one glyceryl ester of nonanoic acid and B) at least one lipase inhibitor.

[0029] Where average values are stated hereinbelow, then, unless stated otherwise, these are number- averaged average values.

[0030] Unless stated otherwise, percentages are data in per cent by weight. The same is true for parts per million (ppm).

[0031] Wherever measurement values are stated hereinbelow, then, unless stated otherwise, these have been determined at a temperature of 25°C and a pressure of 1013 mbar.

[0032] The “nonanoates” in the context of the instant invention preferably are “n-nonanoates”. The quantification of the individual components of the inventive compositions is carried out by a GC / FID analysis according to the following description.

[0033] The contents of glycerol and nonanoic acid are determined quantitatively as weight percent (wt.- %), while the content of diglycerol and all glyceryl and diglyceryl nonanoates as wt.-% are analyzed semi quantitatively by using suitable reference substances as listed below.

[0034] For the analysis, 40 mg glyceryl monolaurate, 30 mg of glyceryl dilaurate, 20 mg of glyceryl tricaprylate (as calibration reference standard for all the glyceryl nonanoates), 25 mg 1 ,3-propanediol (as internal standard for the glycerol quantification) and 100 mg of the respective composition (example 1 to 5) are dissolved in 5 ml of a mixture of pyridine / chloroform (4:1). Then, 0.25 ml of the clear solution are transferred into an autosampler vial. Subsequently, 0.5 ml of N-Methyl-N- (trimethylsilyl)trifluoroacetamide (MSTFA) are being added. The derivatization of the hydroxyl groups is completed by heating to 80°C for 30 min.

[0035] An aliquot of the final sample is analyzed by GC / FID using the following conditions.

[0036] A preferred composition according to the instant invention is characterised in that component A) comprises glyceryl mono-nonanoate, glyceryl di-nonanoate and glyceryl tri-nonanoate.

[0037] Preferably the composition according to the instant invention is characterised in that component A) comprises

[0038] 30 wt.-% - 75 wt.-%, preferably 35 wt.-% - 70 wt.-%, most preferably 40 wt.-% - 60 wt.-% of 1- glyceryl mono-nonanoate

[0039] 1.0 wt.-% - 20 wt.-%, preferably 2.0 wt.-% - 15 wt.-%, most preferably 3.0 wt.-% - 10 wt.-% of 2- glyceryl mono-nonanoate

[0040] 4.0 wt.-% - 30 wt.-%, preferably 7.0 wt.-% - 25 wt.-%, most preferably 9.0 wt.-% - 20 wt.-% of 1 ,2- glyceryl di-nonanoate

[0041] 8.0 wt.-% - 45 wt.-%, preferably 10 wt.-% - 30 wt.-%, most preferably 15 wt.-% - 25 wt.-% of 1 ,3- glyceryl di-nonanoate

[0042] 0.1 wt.-% - 20 wt.-%, preferably 1 .0 wt.-% - 15 wt.-%, most preferably 2.0 wt.-% - 10 wt.-% of glyceryl tri-nonanoate, wherein the percentages by weight refer to all glyceryl ester of nonanoic acid.

[0043] A more preferred composition according to the instant invention is characterised in that characterised in that component A) it comprises

[0044] 40 wt.-% - 60 wt.-% of 1 -glyceryl mono-nonanoate,

[0045] 3 wt.-% - 10 wt.-% of 2-glyceryl mono-nonanoate,

[0046] 9 wt.-% - 20 wt.-% of 1 , 2-glyceryl di-nonanoate, 15 wt.-% - 25 wt.-% of 1 ,3-glyceryl di-nonanoate and 2 wt.-% - 10 wt.-% of glyceryl tri-nonanoate, wherein the percentages by weight refer to all glyceryl ester of nonanoic acid. Preferably the composition according to the instant invention is characterised in that said lipase inhibitor is selected from the group of polyphenols, lactones, glycosides, flavonoides, terpenes, saponins, aromatic acids and organic acid esters.

[0047] Preferably the composition according to the instant invention is characterised in that said lipase inhibitor is a polyphenol selected from the group of (+)gallocatechin (4r-8)-(-)-epicatechin (CAS 79199-56-7), 3,7,3',5'-tetrahydroxyflavone (CAS 67858-31-5); 4'-dehydroxyrobidanol, 5,7,4'- trihydroxy-6,8- diprenylisoflavone (CAS 51225-28-6), 6-c-p-d-boivinopyranoside / chrysoeriol (CAS 491-71-4), 8-c-ascorbyl(-)-epigallocatechin 3-O-gallate (CAS 126715-87-5), ampelopsin I di hydro myricetin (CAS 27200-12-0), cyanidin (CAS 13306-05-3 ), cyanidin chloride (CAS 528-58- 5), cyanidin-3,5-diglucoside (CAS 2611-67-8), cyanidin-3-glucoside (CAS 7084-24-4), daidzein (CAS 486-66-8), delphinidin (CAS 528-53-0), derhamnosylmaysin, fustin (CAS 20725-03-5 ), galangin (CAS 548-83-4), genistein (CAS 446-72-0), hesperidin (CAS 520-26-3), hyperin (CAS 482-36-0 ), isoorientin (CAS 4261-42-1), isoorientin 2-O-a-l-rhamnoside (CAS 50980-94-4), isoquercetin (CAS 482-35-9), kaempferol (CAS 520-18-3), kaempferol-3-glucoside, kaempferol-3- O-p-d-glucuronide (CAS 480-10-4), luteolin (CAS 491-70-3), malvidin (CAS 643-84-5), myricetin (CAS 529-44-2), neohesperidin (CAS 13241-33-3), orientin (CAS 28608-75-5), petunidin (CAS 1429-30-7), procyanidin b-2 (CAS 29106-49-8), delphinidin 3-O-sambubioside chloride (CAS 53158-73-9), procyanidin b-3 (CAS 23567-23-9), prodelphinidin a-2 3'-O-gallate (CAS 126715-94-4 ), prodelphinidin (CAS 86631-36-9), prodelphinidin b-2 3,3'- di-gallate (CAS 86588-89-8), prodelphinidin b-4 , prodelphinidin b-4 3'-O-gallate (CAS 126786-49-0), prodelphinidin b-5 3,3'- di- O-gallate (CAS 86588-87-6), quercetin (CAS 117-39-5), quercetin-arabinoside (CAS 22255-13-6), quercetin-3-O-p-d-arabinopyranosyl-(1 — 2)- p-d-galactopyranoside, quercetin-3-O-p-d- glucuronide (CAS 22688-79-5), quercitrin (CAS 522-12-3), quercitrin gallate, rutin (CAS 153-18-4), theaflavin (CAS 4670-05-7), theaflavin 3,3'-di-O-gallate (CAS 30462-35-2 ), theaflavin 3-O-gallate (CAS 30462-34-1) and pyrogallol (CAS 87-66-1).

[0048] Preferably the composition according to the instant invention is characterised in that said lipase inhibitor is a lactone selected from the group of lipstatin (CAS 96829-59-3), panclicin b (CAS 160700-42-5), valilactone (CAS 113276-96-3 ), ebelactone a (CAS 76808-16-7), ebalactone b (CAS 76808-15-6), esterastin (CAS 67655-93-0), caulerpenyne (CAS 70000-22-5), vibralactone d (CAS 1251748-32-9), galactonolactone, gluconolactone, dihydroxybenzyl butyrolactone, and percyquinnin.

[0049] Preferably the composition according to the instant invention is characterised in that said lipase inhibitor is a glycoside selected from the group of (-) epicatechin (CAS 17334-50-8), (-)-catechin 3-O-gallate (CAS 130405-40-2), (-)-epiafzelechin 3-O-gallate (CAS 108907-43-3), (-)- epigallocatechin 3-O-gallate (CAS 989-51-5), (-)-epicatechin 3-O-(3'-O-methyl)gallate (CAS 83104-86-3), (-)-epicatechin 3-gallate (CAS 863-03-6), (-)-epigallocatechin (CAS 970-74-1), (-)- epigallocatechin (4p-8)- (-)-epicatechin 3-O-gallate, (-)-epigallocatechin 3,5-di-O-gallate, (-)- epigallocatechin 3- O-gallate (4p-8)- (-)-epicatechin 3-O-gallate (CAS 126715-82-0), (-)- epigallocatechin 3- O-p-coumaroate, (-)-gallocatechin 3,5- di-O-gallate, (-)-gallocatechin 3-O- gallate, (-)-robidanol, (+) catechin, apigenin, quercetin, rutoside / rutin and isoquercitrin.

[0050] Preferably the composition according to the instant invention is characterised in that said lipase inhibitor is a saponin selected from the group of Platycodin D, Chikusetsusaponin, Ginsenoside Rb1 , Ginsenoside RH1 , Ginsenoside RG1 , Ginsenoside RG2, Ginsenoside RE, Ginsenoside RH4, Ginsenoide RD, Ginsenoside RG4, Ginsenoside RG6, Ginsenoside Compound K, sessiloside, chiisanoside, triterpenoid saponins copteroside B, hederagenin, 3-O-b-D-glucuronopyranoside 6-0- methyl ester silphioside F, gypsogenin 3-O-b-D-glucuronopyranoside, Dioscin, diosgenin, diosgenin argininate, Diosgenin Dipeptide-33 HCL, prosapogenin A, C and gracillin I, escin, cyclocariosides, oligoglycosides, chakasaponins I, Gypsosaponins A-C, rarasaponins I, II, raraoside A, saponin E1 , Hydrolyzed Ginseng Saponins, Saponinyl Acetosteardimonium Chloride, Pulsatilla Saponin, Starfish Saponins, and Sea Cucumber Saponins

[0051] Preferably the composition according to the instant invention is characterised in that said lipase inhibitor is an aromatic acid selected from the group of caffeic acid (CAS 331-39-5 ), ferulic acid (CAS 537-98-4), p-coumaric acid (CAS 501-98-4 ), sinapic acid (CAS 7362-37-0), caftaric acid (CAS 67879-58-7), rosmarinic acid (CAS 20283-92-5), cinnamic acid (CAS 140-10-3), chlorogenic acid (CAS 327-97-9), mandelic acid (CAS 90-64-2, 611-71-2, 17199-29-0) and gallic acid (CAS 149-91-7).

[0052] Preferably the composition according to the instant invention is characterised in that said lipase inhibitor is an organic acid ester selected from the group of citric acid esters, e.g. triethyl citrate (CAS 77-93-0), tributyl citrate, dilauryl citrate, tribrassicyl citrate, ethyl citrate, furfuralmethyl citrate, laureth-6 citrate, laureth-7 citrate, hydrogenated tallow glyceride citrate, disodium lauryl glucosides hydroxypropyl citrate, hydrogenated palm glycerides citrate, glyceryl oleate citrate and potassium glyceryl tricetearate / citrate.

[0053] A preferred composition according to the instant invention is characterized in that said lipase inhibitor of component B) is comprised in the form of a water soluble extracts selected from the plant species Acer ginnala, Acer mono, Acer pseudosieboldianum, Aconitum pseudolaeve, Actinidia arguta, Adonis palaestina, Aesculus hippocastanum, Aesculus turbinate, Aframomum melegueta, Agastache rugosa, Aleurites moluccana, Alhagi camelorum, Allium tuberosum, Aloe vera, Alpinia officinarum, Alpinia zerumbet, Anchusa azurea, Anthemis palestina, Arachis hypogaea, Aralia cordata, Aralia elata, Archidendron jiringa, Arctium lappa, Arctostaphylos uva- ursi, Ardisia japonica, Artemisia annua, Artemisia scoparia, Artocarpus lakoocha, Asparagus acutifolius, Avena sativa, Averrhoa carambola, Baccharis trimera, Bergenia crassifolia, Beta vulgaris, Betula alba, Brassica nigra, Brassica oleracea, Bulbostylis barbata, Bunium persicum, Calendula officinalis, Camellia japonica, Camellia sinensis, Carex kobomugi, Cartham us oxyacantha, Cassia angustifolia, Cassia auriculata, Cassia mimosoides, Cassia siamea, Castanea crenata, Centella asiatica, Chrysanthemum coronarium, Chukrasia tabularis, Cichorium intybus, Cinnamomum sieboldii, Cinnamomum zeylanicum, Cirsium japonicum, Clematis vitalba, Cnidium officinale, Codonopsis pilosula, Coffea Arabica, Convolvulus althaeoides, Cornus mas, Cornus officinalis, Coscinium fenestratum, Crataegus pinnatifida, Cucurbita pepo, Cudrania tricuspidate, Curcuma longa, Cyclocarya paliurus, Cynara cardunculus, Cynometra cauliflora, Cyperus amuricus, Dendranthema indicum, Dicranopteris linearis, Dioscorea nipponica, Diplotaxis tenuifolia, Elaeagnus macrophylla, Eleusine indica, Eleutherococcus senticosus, Eleutherococcus sessiliflorus, Epimedium koreanum,Equisetum arvense, Equisetum hyemale, Eriocaulon sieboldianum, Eriochloa villosa, Eucalyptus galbie, Eucommia ulmoides, Euonymus alatus, Euonymus sachalinensis, Fagonia arabica, Ferula asafoetida, Ficus carica, Foeniculum vulgare, Gardenia jasminoides, Geranium nepalense, Ginkgo biloba, Glycyrrhiza uralensis, Gypsophila oldhamiana, Helianthus annus, Hypericum triquetrifolium, Ilex paraguariensis, lllicium religiosum, Ixora chinensis, Juglans mandshurica, Juncus effusus, Juniperus communis, Justicia gendarussa, Kochia scoparia, Lagerstroemia indica, Lepidium sativum, Lespedeza cuneata, Levisticum officinale, Liriope platyphylla, Lithospermum erythrorhizon, Lonicera japonica, Lycium chinense, Malus domestica, Malva nicaeensis, Mangifera indica, Medicago sativa, Metastoma candidum, Melissa officinalis, Mentha spicata, Millettia reticulata, Momordica charantia, Momordica cochinchinensis, Morinda citrifolia, Moringa stenopetala, Morus alba, Morus nigra, Myristica fragrans, Myrtus communis, Nelumbo nucifera, Nigella sativa, Olea europeae, Ononis natrix, Origanum syriaca, Origanum vulgare, Orixa japonica, Otostegia persica, Panax ginseng, Panax japonicus, Panax quinquefolium, Papaver rhoeas, Paronychia argentea, Passiflora nitida, Persea americana, Phaseolus vulgaris, Phyla nodiflora, Phyllostachys nigra, Pimpinella anisum, Pistacia vera, Pisum sativum, Platycodi radix, Platycodon grandiflorum , Polygonum cuspidatum, Portulaca oleracea, Potentilla erecta, Prunella vulgaris, Prunus avium, Pueraria lobata, Pueraria thunbergiana, Punica granatum, Pyrus pyrifolia, Quercus infectoria, Raphanus raphanistrum, Raphanus sativus, Rehmannia glutinosa, Reseda alba, Rheum palmatum, Rheum ribes, Rhodiola rosea, Rosa damascene, Rosmarinus officinalis, Rubus coreanus, Salacia reticulate, Salix matsudana, Salvia miltiorrhiza, Salvia officinalis, Salvia spinosa, Sanicula chinensis, Sapindus rarak, Scabiosa tschiliensis, Schisandra chinensis, Scrophularia buergeriana, Senna tora, Setaria italica, Shorea roxburghii, Sigesbeckia glabrescens, Silene vulgaris, Smyrnium olusatrum, Sol an urn lycopersicum, Solanum lyratum, Solidago serotina, Sonchus asper, Sonchus oleraceus, Sorbus commixta, Spilanthes acmella, Taraxacum officinale, Taxus cuspidate, Theobroma cacao, Thuja orientalis, Trachelospermum asiaticum, Trichosanthes kirilowii, Trigonella foenum -graecum, Uncaria macrophylla, Urtica urens, Vaccinium myrtillus, Vigna radiata, Viscum album, Vitis vinifera and Zea mays. A preferred composition according to the instant invention is characterised in that component A) is comprised in an amount of from 5.0 wt.-% - 95 wt.-%, preferably 20 wt.-% - 80 wt.-%, most preferably 30 wt.-% - 70 and wt.-%, and component B) is comprised in an amount of from 5.0 wt.- % - 95 wt.-%, preferably 20 wt.-% - 80 wt.-%, most preferably 30 wt.-% - 70 wt.-%, wherein the percentages by weight refer to the total composition.

[0054] Preferably the composition according to the instant invention is characterised in that it comprises glycerol.

[0055] Preferably said glycerol is comprised in an amount of from 0.005 wt.-% -31 wt.-%, preferably 1 .0 wt.-% - 22 wt.-%, most preferably 3.0 wt.-% - 16 wt.-%, wherein the percentages by weight refer to the total composition.

[0056] A preferred composition according to the instant invention is characterised in that it comprises diglycerol and at least one diglyceryl ester of nonanoic acid, preferably in an amount of from 0 wt.- % - 10 wt.-%, preferably 0.01 wt.-% - 7.0 wt.-%, most preferably 0.15 wt.-% - 5.0 wt.-%, wherein the percentages by weight refer to the total composition.

[0057] The compositions according to the instant invention have outstanding properties useful in a wide variety of formulations; thus, the instant invention provides the use of a composition according to the instant invention for the preparation of a formulation, preferably a cosmetic formulation,

[0058] The formulation prepared by the use of the instant invention preferably comprises a further preservative different from the components of the composition of the instant invention.

[0059] Said further preservative preferably is selected from the group of organic acids (e.g. Sorbic acid or a salt thereof, or an ester thereof), glyceryl esters (e.g. glyceryl caprylate, glyceryl caprate), alkanediols (e.g. ethyleneglycol, propanediol, butanediol, pentanediol, hexanediol), glycerylether (e.g. pentylglycerin, hexylglycerin, heptylglycerin, octylglycerin), aromatic organic compounds (e.g. p-anisic acid, or a salt thereof, benzoic acid and its salts, triclosan, benzyl alcohol, phenoxyethanol, alkylparabenes and their salts in particular their alkalimetal salts such as sodium salts) and formalaldehyde or formaldehyde releasers (e.g. DMDM hydantoin, methylchloroisothiazolinone, methylisothiaszolinone), chlorhexidine, digluconate, methyldibromo glutaronitrile, 5-bromo-5-nitro- 1 ,3-dioxane, dehydroacetic acid, diazolidinyl urea, polyaminopropyl biguanide, quaternium-15, triclosan and the like. As used herein the term ‘preservatives’ is meant to also comprise mixtures of preservatives. Said further preservative preferably is comprised in said formulation in an amount of from 0.01 wt.- % - 10 wt.-%, preferably 0.05 wt.-% - 5.0 wt.-%, most preferably 0.1 wt.-% - 2.0 wt.-%, wherein the percentages by weight refer to the total formulation.

[0060] The formulation prepared by the use of the instant invention preferably has a pH in the range of 2.0 to 10.0, preferably 3.5 to 8.0 particularly preferably 4.0 to 6.5.

[0061] The “pH” in connection with the present invention is defined as the value which is measured for the relevant composition at 22°C after stirring for five minutes using a pH electrode calibrated in accordance with ISO 4319 (1977).

[0062] The instant invention provides the use of a composition according to the instant invention as antimicrobial agent, preferably in a cosmetic formulation. Preferably it is used as antimicrobial agent against micro-organisms selected from the group Pluralibacter gergoviae, Staphylococcus spp., Enterobacter spp., gram-negative proteobacteria, preferably Escherichia coli, Pseudomonas spp., Burkholderia spp., Klebsiella spp., Rhizobium spp., Pluralibacter spp., Enhydrobacter spp., Veillonella spp., and gram-positive bacteria, preferably Enterococcus spp., Lactobacillus spp., Propionibacterium spp., Cutibacterium spp., Corynebacterium spp., Streptococcus spp., Micrococcus spp..

[0063] The composition according to the instant invention in the uses according to the instant invention preferably is used in a concentration of 0.01 wt.-% - 20 wt.-%, preferably 0.1 wt.-% - 10 wt.-%, most preferably 0.2 wt.-% - 6.0 wt.-%, wherein the percentages by weight refer to the sum of component A) and B) in the total formulation.

[0064] The examples adduced hereinafter describe the present invention by way of example, without any intention that the invention, the scope of application of which is apparent from the entirety of the description and the claims, be restricted to the embodiments specified in the examples.

[0065] Examples:

[0066] In the following examples glyceryl pelargonate was used, which was produced as follows: 138 g (1 ,50 mol) of glycerol and 190 g (1 .20 mol) of n-nonanoic acid were heated to 220 °C while stirring and distilling off the reaction water. As soon as the acid value was below 2 mg KOH / g and the reaction mixture was a clear, homogeneous liquid, it was cooled down to 25 °C. The product was a yellowish clear liquid.

[0067] Example 1:

[0068] For the assessment of a synergistic beneficial antimicrobial performance of the combination of component A (Glyceryl Pelargonate) and Component B (Triethyl Citrate) according to the invention, synergy was assessed by exposing bacteria to varying concentrations of the two antimicrobial test substances, as described by Elion et al. 1953. The interaction is mathematically represented by the fractional inhibition concentration (FIC), where a FIC below 1 states synergy (Berenbaum 1980, Berenbaum et al. 1983).

[0069] For this, colony forming units, of Pluralibacter gergoviae, cultured overnight on Muller-Hinton agar (2.0 g beef extract, 17.5 g casein hydrolysate, 1 .5 g starch, 17 g agar and 1 I H2O) were transferred to sterile NaCI [0.9 % [m:m]] to obtain a McFarland standard of 0.5. 100 pl of the bacterial suspension was then diluted in 9.9 ml Muller-Hinton broth.

[0070] Synergy (FIC) determination results:

[0071] Table 1

[0072] The results (Table 1) show that, Component A, namely Glyceryl Pelargonate and Component B, namely Triethyl Citrate, according to the invention (*), surprisingly, combined performed better than the addition of their single performances against Pluralibacter gergoviae.

[0073] Example 2:

[0074] For the assessment of a synergistic beneficial antimicrobial performance of the combination of component A (Glyceryl Pelargonate) and Component B (Gluconolactone) according to the invention, synergy was assessed by exposing bacteria to varying concentrations of the two antimicrobial test substances, as described by Elion et al. 1953. The interaction is mathematically represented by the fractional inhibition concentration (FIC), where a FIC below 1 states synergy (Berenbaum 1980, Berenbaum et al. 1983). For this, colony forming units, of Pluralibacter gergoviae, cultured overnight on Muller-Hinton agar (2.0 g beef extract, 17.5 g casein hydrolysate, 1 .5 g starch, 17 g agar and 1 I H2O) were transferred to sterile NaCI [0.9 % [m:m]] to obtain a McFarland standard of 0.5. 100 pl of the bacterial suspension was then diluted in 9.9 ml Muller-Hinton broth.

[0075] Synergy (FIC) determination results:

[0076] Table 2

[0077] The results (Table 2) show that, Component A, namely Glyceryl Pelargonate, coupled with Component B, namely Gluconolactone, according to the invention (*), surprisingly, combined performed better than the addition of their single performances against Pluralibacter gergoviae.

[0078] Example 3:

[0079] For the assessment of a synergistic beneficial antimicrobial performance of the combination of component A (Glyceryl Pelargonate) and Component B ((-)-epigallocatechin 3-O-gallate) according to the invention, synergy was assessed by exposing bacteria to varying concentrations of the two antimicrobial test substances, as described by Elion et al. 1953. The interaction is mathematically represented by the fractional inhibition concentration (FIC), where a FIC below 1 states synergy (Berenbaum 1980, Berenbaum et al. 1983).

[0080] For this, colony forming units, of Pluralibacter gergoviae, cultured overnight on Muller-Hinton agar (2.0 g beef extract, 17.5 g casein hydrolysate, 1 .5 g starch, 17 g agar and 1 I H2O) were transferred to sterile NaCI [0.9 % [m:m]] to obtain a McFarland standard of 0.5. 100 pl of the bacterial suspension was then diluted in 9.9 ml Muller-Hinton broth.

[0081] Synergy (FIC) determination results:

[0082] Table 3

[0083] The results (Table 3) show that, Component A, namely Glyceryl Pelargonate, coupled with Component B, namely (-)-epigallocatechin 3-O-gallate, according to the invention (*), surprisingly, combined performed better than the addition of their single performances against Pluralibacter gergoviae. Example 4:

[0084] For the assessment of a synergistic beneficial antimicrobial performance of the combination of component A (Glyceryl Pelargonate) and Component B (rosmarinic acid) according to the invention, synergy was assessed by exposing bacteria to varying concentrations of the two antimicrobial test substances, as described by Elion et al. 1953. The interaction is mathematically represented by the fractional inhibition concentration (FIC), where a FIC below 1 states synergy (Berenbaum 1980, Berenbaum et al. 1983).

[0085] For this, colony forming units, of Pluralibacter gergoviae, cultured overnight on Muller-Hinton agar (2.0 g beef extract, 17.5 g casein hydrolysate, 1 .5 g starch, 17 g agar and 1 I H2O) were transferred to sterile NaCI [0.9 % [m:m]] to obtain a McFarland standard of 0.5. 100 pl of the bacterial suspension was then diluted in 9.9 ml Muller-Hinton broth.

[0086] Synergy (FIC) determination results:

[0087] Table 4

[0088] The results (Table 4) show that, Component A, namely Glyceryl Pelargonate, coupled with Component B, namely rosmarinic acid, according to the invention (*), surprisingly, combined performed better than the addition of their single performances against Pluralibacter gergoviae.

[0089] Example 5:

[0090] For the assessment of a synergistic beneficial antimicrobial performance of the combination of component A (Glyceryl Pelargonate) and Component B (Potentilla erecta extract) according to the invention, synergy was assessed by exposing bacteria to varying concentrations of the two antimicrobial test substances, as described by Elion et al. 1953. The interaction is mathematically represented by the fractional inhibition concentration (FIC), where a FIC below 1 states synergy (Berenbaum 1980, Berenbaum et al. 1983).

[0091] For this, colony forming units, of Pluralibacter gergoviae, cultured overnight on Muller-Hinton agar (2.0 g beef extract, 17.5 g casein hydrolysate, 1 .5 g starch, 17 g agar and 1 I H2O) were transferred to sterile NaCI [0.9 % [m:m]] to obtain a McFarland standard of 0.5. 100 pl of the bacterial suspension was then diluted in 9.9 ml Muller-Hinton broth.

[0092] Synergy (FIC) determination results:

[0093] Table 5

[0094] The results (Table 5) show that, Component A, namely Glyceryl Pelargonate, coupled with Component B, namely Potentilla erecta extract, according to the invention (*), surprisingly, combined performed better than the addition of their single performances against Pluralibacter gergoviae.

[0095] Example formulations The formulation constituents in the following compositions are referred to in the form of the generally accepted INCI nomenclature with use of the English terms. All concentrations in the use examples are, unless otherwise indicated, given as % by weight.

[0096] All formulations 1-23 were also formulated as a non-inventive version comprising mono,- di-, and triglycerides of saturated and unsaturated, branched and unbranched C3-8 and saturated and unsaturated, branched and unbranched C10-24 fatty acids, replacing the glyceryl ester of nonanoic acid (Glyceryl Pelargonate).

[0097] Formulation 1

[0098] Formulation 2

[0099] Formulation 3

[0100] Formulation 4

[0101] Formulation 5

[0102] Formulation 6

[0103]

[0104] Formulation 7

[0105] Formulation 8

[0106]

[0107] Formulation 9 Formulation 10

[0108] Formulation 11

[0109] Formulation 12

[0110] Formulation 13

[0111] Formulation 14

[0112] Formulation 15

[0113]

[0114] Formulation 16

[0115] Formulation 17

[0116] Formulation 18

[0117] Formulation 19

[0118] Formulation 20

[0119] Formulation 21 Formulation 22 Formulation 23

Claims

Claims1 . Composition comprisingA) at least one glyceryl ester of nonanoic acid andB) at least one lipase inhibitor.

2. Composition according to claim 1 characterised in that component A) comprises glyceryl mono-nonanoate, glyceryl di-nonanoate and glyceryl tri-nonanoate.

3. Composition according to claim 1 or 2 characterised in that component A) comprises30 wt.-% - 75 wt.-%, preferably 35 wt.-% - 70 wt.-%, most preferably 40 wt.-% - 60 wt.-% of 1- glyceryl mono-nonanoate1 .0 wt.-% - 20 wt.-% , preferably 2.0 wt.-% - 15 wt.-% , most preferably 3.0 wt.-% - 10 wt.-% of 2- glyceryl mono-nonanoate4.0 wt.-% - 30 wt.-%, preferably 7.0 wt.-% - 25 wt.-%, most preferably 9.0 wt.-% - 20 wt.-% of 1 ,2-glyceryl di-nonanoate8.0 wt.-% - 45 wt.-%, preferably 10 wt.-% - 30 wt.-%, most preferably 15 wt.-% - 25 wt.-% of 1 ,3- glyceryl di-nonanoate0.1 wt.-% - 20 wt.-%, preferably 1 .0 wt.-% - 15 wt.-%, most preferably 2.0 wt.-% - 10 wt.-% of glyceryl tri-nonanoate, wherein the percentages by weight refer to all glyceryl ester of nonanoic acid.

4. Composition according to any of the preceding claims characterised in that said lipase inhibitor is selected from the group of polyphenols, lactones, glycosides, flavonoides, terpenes, saponins, aromatic acids and organic acid esters.

5. Composition according to any of the preceding claims characterised in that said lipase inhibitor is a polyphenol selected from the group of (+)gallocatechin (4r-8)-(-)-epicatechin, 3,7,3',5'-tetrahydroxyflavone; 4'-dehydroxyrobidanol, 5,7,4'-trihydroxy-6,8- diprenylisoflavone, 6-c-p-d-boivinopyranoside / chrysoeriol, 8-c-ascorbyl(-)-epigallocatechin 3-O-gallate, ampelopsin / dihydromyricetin, cyanidin, cyanidin chloride, cyanidin-3,5-diglucoside, cyanidin-3-glucoside, daidzein, delphinidin, derhamnosylmaysin, fustin, galangin, genistein, hesperidin, hyperin, isoorientin, isoorientin 2-O-a-l-rhamnoside, isoquercetin, kaempferol, kaempferol-3-glucoside, kaempferol-3-O-p-d-glucuronide, luteolin, malvidin, myricetin, neohesperidin, orientin, petunidin, procyanidin b-2, delphinidin 3-O-sambubioside chloride, procyanidin b-3, prodelphinidin a-2 3'-O-gallate, prodelphinidin, prodelphinidin b-2 3,3'- digallate, prodelphinidin b-4, prodelphinidin b-4 3'-O-gallate, prodelphinidin b-5 3,3'- di-O- gallate, quercetin, quercetin-arabinoside, quercetin-3-O-p-d-arabinopyranosyl-(1 — 2)- p-d- galactopyranoside, quercetin-3-O-p-d-glucuronide, quercitrin, quercitrin gallate, rutin, theaflavin, theaflavin 3,3'-di-O-gallate, theaflavin 3-O-gallate and pyrogallol.

6. Composition according to any of the preceding claims characterised in that said lipase inhibitor is a lactone selected from the group of lipstatin, panclicin b, valilactone, ebelactone a, ebalactone b, esterastin, caulerpenyne, vibralactone d, galactonolactone, gluconolactone, dihydroxybenzyl butyrolactone, and percyquinnin.

7. Composition according to any of the preceding claims characterised in that said lipase inhibitor is a glycoside selected from the group of (-) epicatechin, (-)-catechin 3-O-gallate, (-)-epiafzelechin 3-O-gallate, (-)-epigallocatechin 3-O-gallate, (-)-epicatechin 3-O-(3'-O- methyl)gallate, (-)-epicatechin 3-gallate, (-)-epigallocatechin, (-)-epigallocatechin (4p-8)- (-)-epicatechin 3-O-gallate, (-)-epigallocatechin 3,5-di-O-gallate, (-)-epigallocatechin 3- O- gallate (4p-8)- (-)-epicatechin 3-O-gallate, (-)-epigallocatechin 3- O-p-coumaroate, (-)- gallocatechin 3,5- di-O-gallate, (-)-gallocatechin 3-O-gallate, (-)-robidanol, (+) catechin, apigenin, quercetin, rutoside / rutin and isoquercitrin.

8. Composition according to any of the preceding claims characterised in that said lipase inhibitor is a saponin selected from the group of Platycodin D, Chikusetsusaponin, Ginsenoside Rb1 , Ginsenoside RH1 , Ginsenoside RG1 , Ginsenoside RG2, Ginsenoside RE, Ginsenoside RH4, Ginsenoide RD, Ginsenoside RG4, Ginsenoside RG6, Ginsenoside Compound K, sessiloside, chiisanoside, triterpenoid saponins copteroside B, hederagenin, 3-O-b-D-glucuronopyranoside 6-O-methyl ester silphioside F, gypsogenin 3-O-b-D- glucuronopyranoside, Dioscin, diosgenin, diosgenin argininate, Diosgenin Dipeptide-33 HCL, prosapogenin A, C and gracillin I, escin, cyclocariosides, oligoglycosides, chakasaponinsI, Gypsosaponins A-C, rarasaponins I, II, raraoside A, saponin E1 , Hydrolyzed Ginseng Saponins, Saponinyl Acetosteardimonium Chloride, Pulsatilla Saponin, Starfish Saponins, and Sea Cucumber Saponins.

9. Composition according to any of the preceding claims characterised in that said lipase inhibitor is an aromatic acid selected from the group of caffeic acid, ferulic acid, p-coumaric acid, sinapic acid, caftaric acid, rosmarinic acid, cinnamic acid, chlorogenic acid, mandelic acid and gallic acid.

10. Composition according to any of the preceding claims characterised in that said lipase inhibitor is an organic acid ester selected from the group of citric acid esters, e.g. triethyl citrate, tributyl citrate, dilauryl citrate, tribrassicyl citrate, ethyl citrate, furfuralmethyl citrate, laureth-6 citrate, laureth-7 citrate, hydrogenated tallow glyceride citrate, disodium lauryl glucosides hydroxypropyl citrate, hydrogenated palm glycerides citrate, glyceryl oleate citrate and potassium glyceryl tricetearate / citrate.11 . Composition according to any of the preceding claims characterised in that said lipase inhibitor is comprised in the form of a water soluble extracts selected from the plant species Acer ginnala, Acer mono, Acer pseudosieboldianum, Aconitum pseudolaeve, Actinidiaarguta, Adonis palaestina, Aesculus hippocastanum, Aesculus turbinate, Aframomum melegueta, Agastache rugosa, Aleurites moluccana, Alhagi camelorum, Allium tuberosum, Aloe vera, Alpinia officinarum, Alpinia zerumbet, Anchusa azurea, Anthemis palestina, Arachis hypogaea, Aralia cordata, Aralia elata, Archidendron jiringa, Arctium lappa, Arctostaphylos uva-ursi, Ardisia japonica, Artemisia annua, Artemisia scoparia, Artocarpus lakoocha, Asparagus acutifolius, Avena sativa, Averrhoa carambola, Baccharis trimera, Bergenia crassifolia, Beta vulgaris, Betula alba, Brassica nigra, Brassica oleracea, Bulbostylis barbata, Bunium persicum, Calendula officinalis, Camellia japonica, Camellia sinensis, Carex kobomugi, Carthamus oxyacantha, Cassia angustifolia, Cassia auriculata, Cassia mimosoides, Cassia siamea, Castanea crenata, Centella asiatica, Chrysanthemum coronarium, Chukrasia tabularis, Cichorium intybus, Cinnamomum sieboldii, Cinnamomum zeylanicum, Cirsium japonicum, Clematis vitalba, Cnidium officinale, Codonopsis pilosula, Coffea Arabica, Convolvulus althaeoides, Cornus mas, Cornus officinalis, Coscinium fenestratum, Crataegus pinnatifida, Cucurbit a pepo, Cudrania tricuspidate, Curcuma longa, Cyclocarya paliurus, Cynara cardunculus, Cynometra cauliflora, Cyperus amuricus, Dendranthema indicum, Dicranopteris linearis, Dioscorea nipponica, Diplotaxis tenuifolia, Elaeagnus macrophylla, Eleusine indica, Eleutherococcus senticosus, Eleutherococcus sessiliflorus, Epimedium koreanum,Equisetum arvense, Equisetum hyemale, Eriocaulon sieboldianum, Eriochloa villosa, Eucalyptus galbie, Eucommia ulmoides, Euonymus alatus, Euonymus sachalinensis, Fagonia arabica, Ferula asafoetida, Ficus carica, Foeniculum vulgare, Gardenia jasminoides, Geranium nepalense, Ginkgo biloba, Glycyrrhiza uralensis, Gypsophila oldhamiana, Helianthus annus, Hypericum triquetrifolium, Ilex paraguariensis, lllicium religiosum, Ixora chinensis, Juglans mandshurica, Juncus effusus, Juniperus communis, Justicia gendarussa, Kochia scoparia, Lagerstroemia indica, Lepidium sativum, Lespedeza cuneata, Levisticum officinale, Liriope platyphylla, Lithospermum erythrorhizon, Lonicera japonica, Lycium chinense, Malus domestica, Malva nicaeensis, Mangifera indica, Medicago sativa, Metastoma candidum, Melissa officinalis, Mentha spicata, Millettia reticulata, Momordica charantia, Momordica cochinchinensis, Morinda citrifolia, Moringa stenopetala, Morus alba, Morus nigra, Myristica fragrans, Myrtus communis, Nelumbo nucifera, Nigella sativa, Olea europeae, Ononis natrix, Origanum syriaca, Origanum vulgare, Orixa japonica, Otostegia persica, Panax ginseng, Panax japonicus, Panax quinquefolium, Papaver rhoeas, Paronychia argentea, Passiflora nitida, Persea americana, Phaseolus vulgaris, Phyla nodiflora, Phyllostachys nigra, Pimpinella anisum, Pistacia vera, Pisum sativum, Platycodi radix, Platycodon grandiflorum, Polygonum cuspidatum, Portulaca oleracea, Potentilla erecta, Prunella vulgaris, Prunus avium, Pueraria lobata, Pueraria thunbergiana, Punica granatum, Pyrus pyrifolia, Quercus infectoria, Raphanus raphanistrum, Raphanus sativus, Rehmannia glutinosa, Reseda alba, Rheum palmatum, Rheum ribes, Rhodiola rosea, Rosa damascene, Rosmarinus officinalis, Rubus coreanus, Salacia reticulate, Salix matsudana, Salvia miltiorrhiza, Salvia officinalis, Salvia spinosa, Sanicula chinensis, Sapindus rarak, Scabiosa tschiliensis, Schisandra chinensis, Scrophularia buergeriana, Senna tora, Setaria italica, Shorea roxburghii, Sigesbeckia glabrescens, Silenevulgaris, Smyrnium olusatrum, Solan um lycopersicum, Solan um lyratum, Solidago serotina, Sonchus asper, Sonchus oleraceus, Sorbus commixta, Spilanthes acmella, Taraxacum officinale, Taxus cuspidate, Theobroma cacao, Thuja orientalis, Trachelospermum asiaticum, Trichosanthes kirilowii, Trigonella foenum-graecum, Uncaria macrophylla, Urtica urens, Vaccinium myrtillus, Vigna radiata, Viscum album, Vitis vinifera and Zea mays.

12. Composition according to any of the preceding claims characterised in that component A) is comprised in an amount of from 5.0 wt.-% - 95 wt.-%, preferably 20 wt.-% - 80 wt.-%, most preferably 30 wt.-% - 70 and wt.-%, and component B) is comprised in an amount of from 5.0 wt.-% - 95 wt.-%, preferably 20 wt.-% - 80 wt.-%, most preferably 30 wt.-% - 70 wt.-%, wherein the percentages by weight refer to the total composition.

13. Composition according to any of the preceding claims characterised in that it comprises glycerol, preferably in an amount of from 0.005 wt.-% -31 wt.-%, preferably 1 .0 wt.-% - 22 wt.-%, most preferably 3.0 wt.-% - 16 wt.-%, wherein the percentages by weight refer to the total composition.

14. Composition according to any of the preceding claims characterised in that it comprises diglycerol and at least one diglyceryl ester of nonanoic acid, preferably in an amount of from 0 wt.-% - 10 wt.-%, preferably 0.01 wt.-% - 7.0 wt.-%, most preferably 0.15 wt.-% - 5.0 wt.- %, wherein the percentages by weight refer to the total composition.

15. Use of a composition according to any of the claims 1 to 14 for the preparation of a formulation, preferably a cosmetic formulation or as antimicrobial agent, preferably in a cosmetic formulation, preferably in a concentration of 0.01 wt.-% - 20 wt.-%, preferably 0.1 wt.-% - 10 wt.-%, most preferably 0.2 wt.-% - 6 wt.-%, wherein the percentages by weight refer to the sum of component A) and B) in the total formulation.

Images